During the last week of September 2021, 500 participants in the Contraceptive Technology virtual conference learned about three new contraceptives that I want to tell you about. Innovation means nothing unless it leads to a change in practices. The answer is in the hands of everyone providing contraceptives and of students of this field—offer your patients the option of any of these three exciting new methods: the drospirenone-containing progestin-only pill, the 52 mg LNG IUDs as emergency contraceptives, and Depo SQ for self-injection at home.
Registered for the 2021 Contraceptive Technology Virtual Conference, September 22-24? We look forward to “seeing” you there! Helpful directions follow, and are also available at http://contraceptivetechconf.com/attendee-instructions/.
Need help logging in? Your confirmation email included a user name, password, and login link to access the conference. Be sure to check your spam if you didn’t see it come through. Can’t find it? Email us at conference [at] contraceptivetechnology.com
On any given day, 1 in 5 people has a sexually transmitted infection. It is not unlikely that one of the infected will be seeing you for treatment. Most RTIs exhibit a “biological sexism,” say Jeanne Marrazzo and Ina Park. Women are more likely than men to acquire RTIs, due to the transmission dynamics during an act of vaginal intercourse. For example, the risk of acquiring gonorrhea from a single act of vaginal intercourse (where one partner is infectious) is approximately 25% for men and 50% for women.